Glenmark Expects Cash Surge From License Deals in Next 18 Months

Updated on
  • Diabetes business to grow 30 percent per year next three years
  • Open to transformational acquisition after three or four years

Glenmark Pharmaceuticals Ltd. expects a surge of new cash to hit its books in the next 18 months from licensing out its intellectual property as it seeks to transform from a maker of generic medicines to developing new ones.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.